Abbott Laboratories Q2 2024 Adj EPS $1.14 Beats $1.10 Estimate, Sales $10.377B Beat $10.371B Estimate
Portfolio Pulse from Benzinga Newsdesk
Abbott Laboratories reported Q2 2024 adjusted EPS of $1.14, beating the estimate of $1.10. Sales were $10.377 billion, also surpassing the estimate of $10.371 billion.
July 18, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott Laboratories reported better-than-expected Q2 2024 results with an adjusted EPS of $1.14 and sales of $10.377 billion, both surpassing estimates.
The better-than-expected earnings and sales figures are likely to positively impact Abbott Laboratories' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100